Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorDana-Farber Cancer Institute
About this trial
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Eligibility criteria
Qualifiers
Age 45 and under at lung cancer diagnosis
Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
Provision of written informed consent
Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
Disqualifiers
Individuals who decline to sign consent
Individuals who are unable to give consent or assent and are without a designated healthcare proxy
Compromise of patient diagnosis or staging if tissue is used for research
Trial design
Treatments tested in this trial
- Data and Specimen Collection
Treatment groups
500 Participants
are divided into 1 treatment groupLocations
4Beth Israel Deaconess Medical Center02115, BostonMassachusetts, United States
Brigham and Women's Hospital02115, BostonMassachusetts, United States
Dana-Farber Cancer Institute02115, BostonMassachusetts, United States
Massachusetts General Hospital02114, BostonMassachusetts, United States
Sponsors and collaborators
Dana-Farber Cancer Institute
Lead sponsor
Source ClinicalTrials.gov